pSivida Corp Announces Fourth Quarter and Fiscal Year 2015 Financial Results Release Date and Conference Call Information
September 02 2015 - 8:00AM
Business Wire
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the
development of sustained release drug delivery products for
treating eye diseases, today announced that its financial results
for the fourth quarter and fiscal year 2015 will be released after
the market close on Wednesday, September 9, 2015, followed the same
day by a conference call and live webcast scheduled for 4:30 p.m.
ET.
The conference call may be accessed by dialing (877) 312-7507
from the U.S. and Canada, or (631) 813-4828 from international
locations. The conference ID is 27613566. A live webcast will be
available on the Investor Relations section of the corporate
website at http://www.psivida.com.
A replay of the call will be available beginning September 9,
2015, at approximately 7:30 p.m. ET and ending on September 16,
2015, at 11:59 p.m. ET. The replay may be accessed by dialing (855)
859-2056 within the U.S. and Canada or (404) 537-3406 from
international locations, Conference ID Number: 27613566. A replay
of the webcast will also be available on the corporate website
during that time.
About pSivida Corp.
pSivida Corp. (www.psivida.com), headquartered in Watertown, MA,
is a leader in the development of sustained release, drug delivery
products for treating eye diseases. pSivida has developed three of
only four FDA-approved treatments for back-of-the-eye diseases. The
most recent, ILUVIEN®, a micro-insert for diabetic macular edema,
is licensed to Alimera Sciences and sold in the U.S. and three EU
countries. Retisert®, an implant for posterior uveitis, is licensed
to and sold by Bausch & Lomb. pSivida’s lead product
candidate, Medidur™, a micro-insert for posterior uveitis, is in
Phase III clinical trials with an NDA anticipated as early as the
first half of 2017. pSivida’s pre-clinical development program is
focused on using its core platform technologies, Durasert™ and/or
Tethadur™, to deliver drugs and biologics to treat wet and dry
age-related macular degeneration (AMD), glaucoma, osteoarthritis
and other diseases.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995: Various statements made in this release are
forward-looking, and are inherently subject to risks, uncertainties
and potentially inaccurate assumptions. All statements that address
activities, events or developments that we intend, expect or
believe may occur in the future are forward-looking statements.
Some of the factors that could cause actual results to differ
materially from the anticipated results or other expectations
expressed, anticipated or implied in our forward-looking statements
include uncertainties with respect to: actual final IOP safety
results for Medidur Phase III trials; ability to achieve profitable
operations and access to capital; fluctuations in operating
results; further impairment of intangible assets; decline in
Retisert royalties; successful commercialization of, and receipt of
revenues from, ILUVIEN for DME; effect of pricing and reimbursement
decisions on sales of ILUVIEN for DME; consequences of flucinolone
acetonide side effects; number and cost of clinical trials and data
necessary to support an NDA for, approval by Indian regulators of
the trial design for, timing of filing the NDA for, and regulatory
approval and successful commercialization of, Medidur; delays in
completion of clinical trials; increases in cost of clinical
trials; changes in, or misunderstandings with respect to, FDA
guidance on required clinical trials; development of the
Latanoprost Product and any exercise by Pfizer of its option;
ability of Tethadur to successfully deliver large biologic
molecules and to develop products using it; ability to successfully
develop product candidates, complete clinical trials and receive
regulatory approvals; ability to market and sell products; success
of current and future license agreements; termination of license
agreements; effects of competition and other developments affecting
sales of products; market acceptance of products; effects of
guidelines, recommendations and studies; protection of intellectual
property and avoiding intellectual property infringement; retention
of key personnel; product liability; industry consolidation;
compliance with environmental laws; manufacturing risks; risks and
costs of international business operations; legislative or
regulatory changes; volatility of stock price; possible dilution;
absence of dividends; and other factors described in our filings
with the SEC. You should read and interpret any forward-looking
statements together with these risks. Should known or unknown risks
materialize, or should underlying assumptions prove inaccurate,
actual results could differ materially from past results and those
anticipated, estimated or projected in the forward-looking
statements. You should bear this in mind as you consider any
forward-looking statements. Our forward-looking statements speak
only as of the dates on which they are made. We do not undertake
any obligation to publicly update or revise our forward-looking
statements even if experience or future changes makes it clear that
any projected results expressed or implied in such statements will
not be realized.
Follow pSivida on social media:
Twitter: https://twitter.com/pSividaCorp
Facebook:
https://www.facebook.com/pages/PSivida-Corp/544893792199562
LinkedIn: http://www.linkedin.com/company/psivida
Google+:
https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts
The President's Blog:
http://www.thechairmansblog.com/paul-ashton
For more information on pSivida, visit www.psivida.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150902005346/en/
Martin E. Janis & Company, Inc.Beverly JedynakPresidentT:
312-943-1123M: 773-350-5793bjedynak@janispr.com
Psivida Corp (ASX:PVA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Psivida Corp (ASX:PVA)
Historical Stock Chart
From Jul 2023 to Jul 2024